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The average treatment effect of antidepressants in major depression was found to be about
2 points on the 17-item Hamilton Depression Rating Scale, which lies below clinical rele-
vance. Here, we searched for evidence of a relevant treatment effect heterogeneity that
could justify the usage of antidepressants despite their low average treatment effect.
Methods
Bayesian meta-analysis of 169 randomized, controlled trials including 58,687 patients. We
considered the effect sizes log variability ratio (lnVR) and log coefficient of variation ratio
(lnCVR) to analyze the difference in variability of active and placebo response. We used
Bayesian random-effects meta-analyses (REMA) for lnVR and lnCVR and fitted a random-
effects meta-regression (REMR) model to estimate the treatment effect variability between
antidepressants and placebo.
Results
The variability ratio was found to be very close to 1 in the best fitting models (REMR: 95%
highest density interval (HDI) [0.98, 1.02], REMA: 95% HDI [1.00, 1.02]). The between-
study standard deviation τ under the REMA with respect to lnVR was found to be low (95%
HDI [0.00, 0.02]). Simulations showed that a large treatment effect heterogeneity is only
compatible with the data if a strong correlation between placebo response and individual
treatment effect is assumed.
Conclusions
The published data from RCTs on antidepressants for the treatment of major depression is
compatible with a near-constant treatment effect. Although it is impossible to rule out a sub-
stantial treatment effect heterogeneity, its existence seems rather unlikely. Since the
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average treatment effect of antidepressants falls short of clinical relevance, the current pre-
scribing practice should be re-evaluated.
Introduction
Major depressive disorder is one of the most frequent psychiatric conditions and poses a
major burden for individuals and society; it affects more than 300 million people worldwide
and is ranked as the single largest contributor to disability [1]. The first-line treatment usually
consists of psychotherapy and/or pharmacotherapy with antidepressant drugs [2, 3]. Within
the last decades, the number of prescriptions of antidepressants has continuously increased in
several regions of the world. A recent meta-analysis by Cipriani et al. comprising 522 random-
ized, controlled trials (RCTs) of 21 antidepressants in 116,477 participants reported that all
antidepressants were more effective than placebo in reducing depressive symptoms [4]. How-
ever, the so-called average treatment effect, which measures the difference in mean outcomes
between active and control group, was only about 2 points on the 17-item Hamilton Depres-
sion Rating Scale (HAMD-17) [5] in this dataset [6]. A reduction of 2 points on the HAMD
scale is probably not detectable by the treating physician and of questionable clinical relevance.
According to Leucht et al. [7], a reduction of up to 3 points on the HAMD corresponds to “no
change” in the Clinical Global Impressions—Improvement Scale (CGI-I) and the assumed
threshold of clinical significance is between 3 and 7 points [8, 9].
Treatment effect heterogeneity
Despite the small average treatment effect of antidepressants, it is commonly assumed that
subpopulations of patients exist that have a clinically relevant benefit. However, a clinically rel-
evant treatment effect heterogeneity, albeit widely believed and intuitively plausible, has not
conclusively been shown to exist yet. The observed change in clinical symptomatology (the
change or response score), which is highly variable, is the sum of different effects, such as pla-
cebo effect, regression to the mean, spontaneous remission and treatment effect [10, 11].
Hence, the true effect of an intervention cannot be observed in a single patient, as it would
require the observation (and subtraction of) both potential outcomes–with and without the
intervention. This Fig 1 illustrates the relationship between observed change, individual treat-
ment effect and treatment effect heterogeneity.
The variability ratio
In order to assess treatment effect heterogeneity from the data of parallel group trials, the com-
parison of outcome variances between the active and the control condition has been proposed
[10]. Two different effect size statistics have been suggested to estimate the difference in vari-
ability between two groups [12]. The variability ratio (VR) is the quotient of the variances of
the active and placebo groups, while the coefficient of variance ratio (CVR) corrects for differ-
ences in means between the groups. Here, an increase or a decrease in variance in the active
group might be a signal of a varying individual treatment effect.
Following a recent publication by Winkelbeiner et al. [13], analyzing differences in vari-
ances in 52 randomized, placebo-controlled antipsychotic drug trials, this work aimed at esti-
mating the degree of treatment effect heterogeneity of antidepressants using the open dataset
of the largest meta-analysis of the efficacy of antidepressants in major depressive disorder.
Three other research groups [14–16] have addressed the same question of treatment effect het-
erogeneity of antidepressants using the same dataset.
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However, all previous analyses did not sufficiently take into account the linear association
between the logarithmic mean and logarithmic standard deviation (SD) of the underlying
measuring scale when estimating the direct effect of antidepressants on outcome variability.
The VR and the CVR effect sizes naively assume a slope coefficient of 0 and 1 on this associa-
tion, respectively, and may thus yield biased results if the slope coefficient differs from the
assumed one. Crucially, using the VR in this dataset suggests no evidence for treatment effect
heterogeneity [14, 15], while using the CVR leads to the conclusion of a variable antidepressant
treatment effect [16].
We reanalyzed the Cipriani dataset by implementing a Bayesian meta-regression that mod-
els the degree of linear association between lnMean and lnSD directly from the data and thus
yields more accurate results. We illustrated the exact relationship between VR and CVR and
their respective limitations and disentangled direct and indirect effect of antidepressants on
outcome variability. We showed that the CVR is a suboptimal measure, as it makes strong
assumptions that are not warranted in this dataset. Furthermore, we investigated the compati-
bility of the results with different degrees of treatment effect heterogeneity using simulations
Fig 1. Visualization of potential outcomes and treatment effect for a patient in an antidepressant trial. The patient
is randomized to either the placebo or the active arm, corresponding to two hypothetical “potential outcomes” (Red
scores). Only one outcome can be observed, as a patient cannot receive both interventions simultaneously. The
difference between the two outcomes is the “individual treatment effect” of the intervention (Dark green score). The
individual treatment effect is unobservable and can be imaged to be drawn from hypothetical distributions of the
treatment effect. The variance of this distribution corresponds to the treatment effect heterogeneity. The factor ρ is the
correlation between the placebo response and the individual treatment effect. All numbers signify depression severity
on the HAMD-17 scale.
https://doi.org/10.1371/journal.pone.0241497.g001
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experiments. Using an analytically derived formula, we provided an upper bound on the treat-
ment effect heterogeneity based on the VR estimate.
Methods
Statement of ethics
The authors have no ethical conflicts to disclose.
Data acquisition
We obtained the dataset of the meta-analysis by Cipriani et al. [4] from the Mendeley database
(https://data.mendeley.com/datasets/83rthbp8ys/2). This study included 522 RCTs comparing
21 antidepressants with placebo or another active antidepressant as oral monotherapy for the
acute treatment of adults (�18 years old and of both sexes) with a primary diagnosis of major
depressive disorder according to standard operationalized diagnostic criteria (Feighner crite-
ria, Research Diagnostic Criteria, DSM-III, DSM-III-R, DSM-IV, DSM-5, and ICD-10). For
further details on the inclusion criteria and study characteristics, see the original study. We did
not attempt to obtain individual patient data but relied on summary data from the openly
accessible dataset.
Data extraction and processing
Of the total of 522 studies we kept the 304 that included a placebo arm. We excluded all studies
for which the reported endpoint did not represent the change from baseline, leaving us with a
total of 169 studies including 58,687 patients for the analysis (see PRISMA flow diagram, Fig
2). We extracted both the mean and the standard deviation of pre- and post-treatment out-
come difference scores (the “response”). The studies included in the data set comprised 8 dif-
ferent depression scales, namely HAMD-17, HAMD-21, HAMD-24, HAMD unspecified,
HAMD-29, HAMD-31, Montgomery–Åsberg Depression Rating Scale (MADRS) [17] and
IDS-IVR-30 [18]. Studies with different treatment arms were aggregated according to the rec-
ommendation of the Cochrane Collaboration. In this manuscript, we define response as pre-
post-difference of a given outcome scale.
Investigation of treatment effect heterogeneity
In the case of a constant treatment effect, the variances of the active and the placebo group are
expected to be equal. Therefore, a large difference in variances in response to antidepressants
and placebo may be regarded as evidence of treatment effect heterogeneity.
Two different effect size statistics have been suggested by Nakagawa et al. [12] to estimate
the difference in variability of active and placebo response:












SD ¼ standard deviation; a ¼ active; p ¼ placebo
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; where : CV ¼
SD
mean
The VR measures the total effect (direct and indirect) of antidepressants on outcome vari-
ability. If the mean and standard deviation of the outcome scale are associated, the active treat-
ment would have an indirect effect on the outcome variability mediated by its effect on the
outcome mean. In order to estimate only the direct effect of the treatment on outcome vari-
ability, it is therefore necessary to control for the mean ~ SD relationship (Fig 3).
The lnCVR controls for such an association but implicitly assumes a linear relationship
between lnMean and lnSD with slope coefficient of 1. For clarification, consider a linear
Fig 2. PRISMA 2009 flow diagram.
https://doi.org/10.1371/journal.pone.0241497.g002
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relationship between lnMean and lnSD across different studies with slope coefficient 1:
lnSD ¼ const þ lnMean






Therefore, the lnCVR can be represented by a linear function between lnVR and lnRR with
slope coefficient 1:
lnCVR ¼ consta   constp ¼ a
lnVR   lnRR ¼ a
lnVR ¼ aþ 1 � lnRR
Conversely, the lnVR can be represented by a linear function between lnVR and lnRR with
slope coefficient 0:
lnVR ¼ aþ 0 � lnRR
Where lnRR is defined as:





; where mean denotes the mean of the response variable
The lnCVR may therefore give biased results when estimating the direct effect, if the slope
coefficient of this linear association differs from 1. Conversely, the lnVR effect size may yield
biased results, if one is interested in the direct effect only and an lnMean ~ lnSD relationship
exists. This is a relevant limitation of both effect sizes that has not been considered by previous
analyses.
Fig 3. Causal graph depicting relationship between treatment, mean and SD. The treatment Tx has a causal effect of
around 2 Hamilton points on the mean of the study population. If we control for the mean ~ SD relationship when
estimating the variability between treatment and control, we only measure the direct effect of treatment on variability,
while no such control (as with the VR effect size) measures the total effect of the treatment on outcome variability.
https://doi.org/10.1371/journal.pone.0241497.g003
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Linear association between lnMean and lnSD
The CVR effect size implicitly assumes a linear association between the logarithm of the mean
response scores (lnMean) and the logarithm of their standard deviation (lnSD) with a slope coef-
ficient of 1. In order to test this assumption, we investigated this association by using a varying
intercept model, where the intercepts were allowed to vary between studies with different depres-
sion scales. Moreover, testing for a linear association between lnMean and lnSD helps assessing
the validity of the exchangeability assumption of random-effects meta-analyses. If there is a
strong influence of lnMean on lnSD, the lnVR meta-analysis may yield biased results [19].
Statistical analysis
All statistical analyses were carried out in the programming language Python (version 3.7) and
the probabilistic programming language Stan (with pystan version 2.19.1.1 as a Python inter-
face). The python code is available at: https://github.com/volkale/adv.
We used a Bayesian approach to fit all our models using weakly informative priors. Firstly,
we used a Bayesian random-effects meta-analyses (REMA) for the two effect statistics lnVR
and lnCVR. Secondly, we used a Bayesian random-effects meta-regression (REMR) to fit the
lnVR effect statistic with the natural logarithm of the response ratio (lnRR) as a regressor. An
additional complexity in our analysis, as compared to recent analyses [13, 20], came from the
fact that our data set contained several different depression scales (several versions of the
HAMD and the MADRS, see S1 Fig). For our analysis we made the assumption that these dif-
ferent scales are (locally) linearly transformable into each other. This assumption is well sup-
ported by the literature [21]. Fortunately, the lnVR and lnCVR effect statistics are invariant
under linear transformations of the outcome scale.
Random-effects meta-analysis (REMA)
We applied a Bayesian random-effects meta-analysis in order to estimate the effect sizes lnVR
and lnCVR. For the REMA, the following model was applied, where μ equals the underlying
mean of the effect size. Finally, τ2 represents the between-study-variance.
ESi � Nðai; SD
2
i Þ
ai � Nðm; t
2Þ
We specified the following weakly-informative hyper-priors:
m � Cauchyð0; 1Þ
t � HalfCauchyð0; 1Þ
Random-effects meta-regression (REMR)
This approach is a “contrast-based” version of the “arm-based” meta-analysis in Nakagawa et al.
[12] which models the log of the standard deviation of the outcome directly in a multi-level meta-
regression. The advantage of this model over the lnVR and lnCVR meta-analyses is that we are
not forced to make rigid assumptions about the lnMean ~ lnSD association, as the strength of this
relationship is estimated directly from the data. The REMR models this relationship as follows:
lnVR ¼ aþ b � lnRR
Note that the lnVR corresponds to a β coefficient set to 0, whereas the lnCVR corresponds
to a β coefficient set to 1. In the REMR, the slope β can take any real value and is estimated
PLOS ONE On the treatment effect heterogeneity of antidepressants in major depression
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from the data. The contrast-based approach takes care of the issue of the occurrence of differ-
ent depression scales, as it considers relative differences between active and placebo arms
within each study. Since the depression scales are linearly transformable into each other, those
relative differences do not depend on the depression scale.
We used the following model, where lnVRi is the measured lnVR of study i and lnνi is the
true value of lnVRi. αi is the study-specific direct effect, whereas μ denotes the meta-analytic
direct effect. β is the slope coefficient of lnri (the true value of lnRRi), β�lnri thus equals the
study-specific indirect effect.




lnvi ¼ ai þ b � lnri
ai � Nðm; t
2Þ
lnri � Nð0; 2:5
2Þ




We specified the following weakly-informative hyper-priors:
m � Cauchyð0; 1Þ
b � Cauchyð0; 1Þ
t � HalfCauchyð0; 1Þ
Random-effects vs. fixed-effect model
When investigating the heterogeneity of a treatment effect, the choice between a random-
effects and a fixed-effect approach has relevant consequences for the interpretation of the
results. The random-effects model assumes that the treatment effect varies between popula-
tions and studies and hence estimates the average intervention effect [22]. It is a matter of
interpretation, if we consider the between-study-variance to be a results of sampling error or a
true variation of the effect. In the latter case, the between-study variance τ2 and not only the
mean variability may be considered in order to estimate treatment effect heterogeneity.
Choice of priors
Since the number of studies in this meta-analysis was very large relative to the number of model
parameters, we chose regularizing, minimally informative priors. In order to test the sensitivity of
the results to the choice of prior, we repeated the main analysis (REMR) using an enthusiastic
prior as suggested by Spiegelhalter et al. [23]. Specifically, we used a normal prior centered at eμ =
2 (eμ being the meta-analytic direct effect on the non-log scale) with a variance such that the prior
probability of eμ being smaller than 1 was less than 5%. This can roughly be interpreted as expect-
ing a VR of larger than 1 with 95% certainty and a mean estimate of 2 prior to seeing the data.
Model performance
In order to compare the performance of the different models applied, we used the so-called
widely applicable information criterion (WAIC). This method estimates the pointwise
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prediction accuracy of fitted Bayesian models. Here, higher values of WAIC indicate a better
out-of-sample predictive fit (“better” model). We refer to Vehtari et al. [24] for more details on
WAIC.
Influence of baseline severity
Because baseline severity has been implied as a potential moderator on the treatment effect of
antidepressants, we included it as a predictor in the meta-regression model. We expressed the
baseline severity as a fraction of the respective maximum value, in order to account for the
occurrence of different depression scales (S1 Table in S1 File). This yielded the model below,
where BLi is the normalized baseline severity of study i and γ the slope coefficient for the influ-
ence of the baseline severity on outcome variability ratio.
lnvi ¼ ai þ b � lnri þ g � BLi
For this analysis, we excluded studies for which no baseline scores were available and those
that used the scale “Hamilton unspecified”, leaving a total of 152 studies. The baseline severity
scores were normalized according to their respective maximum values.
Subgroup analysis
In order to investigate the influence of the type of antidepressant of outcome variability, we
conducted subgroup analyses applying the REMR model for the following antidepressant clas-
ses: SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline, 89 tri-
als), SSNRI (desvenlafaxine, duloxetine, milnacipran, venlafaxine, 47 trials), tricyclics
(amitriptyline, clomipramine, 11 trials) and atypicals/others (agomelatine, bupropion, mirta-
zapine, nefazodone, reboxetine, trazodone, vortioxetine, 60 trials).
Upper bound on the treatment effect heterogeneity
In order to investigate the compatibility of different assumptions regarding the treatment
effect with the measured variability ratio, we used the following equation that was derived by
A. Volkmann [25]:
v2   1 ¼
ðSDte þ r � SDpÞ
2
SD2P
  r2; where te ¼ individual treatment effect
Simulation experiments
For each simulation, the response under placebo of 1000 patients was drawn from a right
skewed distribution with mean and standard deviation of 8.8 and 7.7 points on the HAMD-17
scale (based on Cipriani data [4]), respectively. For each patient, an individual treatment effect
was computed from a mixed Gaussian distribution with a standard deviation SDte, where the
outcome under placebo and the individual treatment effect were required to be correlated by
the correlation coefficient ρ. This yielded a potential outcome under placebo and a potential
outcome under active treatment for every patient with a corresponding individual treatment
effect (see Fig 1 for illustration). Note that only one of these two outcomes can be observed in
a real experiment. Half of the patients were then randomly selected for treatment; the other
half was assigned to placebo.
For a large treatment effect heterogeneity, the individual treatment effect was drawn from a
distribution with an (arbitrarily chosen) standard deviation SDte = 6.5 HAMD-17. For a low
treatment effect heterogeneity SDte was 1.5 HAMD-17 points.
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Results
Study selection
We included 169 placebo-controlled studies that reported mean and standard deviation of
change in depression scores. These studies included data on 58,687 patients treated with 21
different antidepressants.
Correlation between mean and standard deviation of depression scores
In order to test the model assumptions of the lnVR and lnCVR meta-analyses, we investigated
the linear association between the logarithm of the mean response scores (lnMean) and the
logarithm of their standard deviation (lnSD). Fitting a varying intercept model with lnMean as
independent variable and lnSD as dependent variable, we got a posterior mean for the slope
coefficient of 0.10 with a 95% HDI (highest density interval) interval of [0.04, 0.16]. Fig 4
depicts the linear regression for each depression scale individually. We remark that simply
computing the correlation of the two quantities without paying attention to the correct weight-
ing and the different scales in the data would yield an overestimated slope coefficient of 0.25
(see S2 Table in S1 File). These results imply that the lnCVR likely produces biased results, as it
assumes a slope coefficient of 1 on this association. The SD will therefore be underestimated in
the group with the larger mean (In our case in the antidepressant group). When estimating the
direct effect, the lnVR will overestimate the SD in this group, but to a lesser degree, as the esti-
mated slope coefficient of 0.1 is relatively close to 0, which is the slope coefficient assumed by
the lnVR.
Fig 4. Linear association between lnMean and lnSD. Linear association between lnMean and lnSD using a varying
intercept model, where the intercepts were allowed to vary between studies with different depression scales. Red dots
represent active groups, blue dots represent placebo groups.
https://doi.org/10.1371/journal.pone.0241497.g004
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Log variability ratio (lnVR) and log coefficient of variation (lnCVR)
models
In order to estimate the difference in variability between antidepressant and placebo response,
we modelled the lnVR effect size using a Bayesian random effects model as heterogeneity
between studies may be expected. The posterior mean estimate for the variability ratio was
1.01, with the 95% highest posterior density (HDI) interval ranging from 1.00 to 1.02. The
lnCVR REMA showed a reduction in the coefficient of variation in the active versus the pla-
cebo group (posterior mean estimate for CVR: 0.82, 95% HDI [0.80,0.84]). As predicted, it
underestimates the variance in the active group.
Random-effects meta-regression
Finally, we implemented a Bayesian random effects meta-regression (REMR) that incorporates
the strength of the lnMean ~ lnSD relationship directly from the data. The Bayesian shrinkage
model is depicted in S2 Fig. Fitting this model, we obtained posterior statistics for the μ and β
coefficients (see S3 Table in S1 File and Fig 5). The posterior mean estimate for eμ was 1.00
(95% HDI [0.98,1.02]) and that for β 0.04 (95% HDI [-0.03,0.12]), where we can (roughly, up
to measurement error and study-specific variation) interpret the coefficients as follows:
VR � em � RRb ðlnVR � mþ b � lnRRÞ
Note that the lnVR REMA corresponds to a lnVR REMR with a β coefficient set to 0,
whereas the lnCVR REMA corresponds to a lnVR REMR with a β coefficient set to 1. The
REMR model learns the β coefficient and its posterior mean is equal to 0.04 [-0.03, 0.12] sug-
gesting that the lnVR REMA is a more appropriate model than the lnCVR REMA when mea-
suring the direct effect on outcome variability. Fig 6 shows the estimates for eμ for the different
models.
Fig 5. Posterior credible intervals for total effect, direct effect and indirect effect as determined by the REMR. eα
represents the study-specific direct effect, RRβ the study-specific indirect effect, eμ is the meta-analytic mean of the
direct effect.
https://doi.org/10.1371/journal.pone.0241497.g005
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We observed that the lnVR REMA and the lnVR REMR outperformed the lnCVR REMA
with respect to the WAIC, while the lnVR REMA and the lnVR REMR showed comparable
performance. Fig 7 shows the logWAIC for the different models. S4 Table in S1 File depicts
the detailed results.
Between-study heterogeneity
The between-study standard deviation τ under the REMA was found to be low for lnVR (95%
HDI [0.00,0.02]). Indeed, applying a fixed effects model instead of the REMA for the purpose
of sensitivity analysis yielded similar results for the overall mean estimate of lnVR. Heteroge-
neity was higher for lnCVR (95% HDI for τ [0.05,0.12]).
Influence of baseline severity
We included the baseline severity as a predictor in the meta-regression model, in order to esti-
mate its influence on outcome variability (Fig 8). The posterior interval for its regression coef-
ficient γ in the meta-regression was -0.01 (95% HDI [-0.21,0.20], S5 Table in S1 File),
suggesting no clear influence of baseline depression severity on outcome variability. The inter-
pretation of the parameter γ is as follows, where BL denotes the baseline severity:
VR � em � RRb � ðeBLÞgðlnVR � mþ b � lnRRþ g � BLÞ:
Subgroup analysis
In search of treatment effect heterogeneity of individual antidepressant classes, we repeated
the main analysis (REMR) for each class. The meta-analytic direct effect was not credibly dif-
ferent from 1 for any of the antidepressant classes (Fig 9). For atypicals, SSRI and SSNRI, it
was credibly near 1 (95% HDI [0.96, 1.02], [0.97, 1.05] and [0.96, 1.05], respectively). For tri-
cyclics the mean estimate of the direct effect on variability was 0.91 but with a very wide poste-
rior interval (95% HDI [0.60,1.28]), making this estimate very uncertain.
Fig 6. Posterior credible intervals for the eμ parameter for the different models. REMA: random-effects meta-analysis. FEMA: fixed-effects meta-analysis. REMR:
random-effects meta-regression. The lnCVR underestimates the variability in the active group, while the results are very similar for the REMR and the lnVR meta-
analysis.
https://doi.org/10.1371/journal.pone.0241497.g006
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Sensitivity analysis
Using an enthusiastic prior in the main analysis did not alter the results (eμ = 1.00 (95% HDI
[0.98,1.02])).
Upper bound on treatment effect heterogeneity
Using inequation 5 from the methods section, we derived an upper bound on the treatment
effect heterogeneity. Using the Cipriani et al. dataset, we can estimate SDp (SD of placebo
response) to be equal to around 7.66 on the HAMD-17 scale. From our main analysis we have
that the upper bound of the 95% HDI of the posterior distribution of VR (more accurately eμ)
is 1.02. This implies the following inequality:





Which distributions of the treatment effect are possible for a VR 1.02?
Based on formula 6, Table 1 depicts different magnitudes of treatment effect heterogeneity
compatible with an average treatment effect of 2.0 HAMD17 points and a VR of 1.02.
Fig 7. Widely applicable information criterion (WAIC) depicted on a logarithmic scale. Higher values signify a better predictive fit of the
underlying model. Bars indicate standard errors. REMA: random-effects meta-analysis. FEMA: fixed-effects meta-analysis. REMR: random-
effects meta-regression.
https://doi.org/10.1371/journal.pone.0241497.g007
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The left column (“any distribution”) of the table depicts the upper bound for the standard
deviation of the treatment effect, without any assumptions regarding the shape of its distribu-
tion. The mid column shows the respective percentage of patients with a treatment effect
Fig 8. Influence of baseline severity on outcome variability. Estimated VR of antidepressants versus placebo as a
function of baseline severity on the HAMD17-scale as determined by the REMR. Depicted are the mean estimates and
95% HDIs for three different values of the response ratio (mean response active versus mean response placebo). The
meta-analytic mean of RR is around 1.22 in the Cipriani data set.
https://doi.org/10.1371/journal.pone.0241497.g008
Fig 9. VR for different antidepressant classes. Posterior credible intervals for the eμ parameter for different
antidepressant classes as determined by the random-effect meta-regression.
https://doi.org/10.1371/journal.pone.0241497.g009
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greater than 7 HAMD points when assuming a normally distributed treatment effect. The
right column assumes a dichotomous treatment effect (“responder”, “non-responder”). Here,
“non-responders” are assumed to have a treatment effect of 0 (placebo
response = antidepressant response), whereas “responders” have a fixed treatment effect > 0.
The percentage of “responders” and their respective “responder treatment effect” depend
upon the intra-individual correlation ρ between the potential outcome placebo response and
individual treatment effect.
These results show that, contrary to intuition, a variability ratio of 1.02 is (theoretically)
compatible with a standard deviation of the treatment effect between 0 and 15.5 points on the
HAMD-17 scale. Conversely, a reduction in the variability in the treatment group is compati-
ble with a substantial treatment effect heterogeneity if response under placebo and individual
treatment effect are negatively associated (see simulations in S5 and S6 Figs).
Simulations
We conducted simulation experiments in order to illustrate the compatibility of a VR of 1.02
with different degrees of treatment effect heterogeneity. For a large TEH with SDte = 6.5
HAMD-17, the response under placebo and the individual treatment effect have to be nega-
tively correlated by the correlation factor ρ = - 0.4, in order for the VR to credibly remain at or
below 1.02 (see Table 1). Fig 10 depicts the change scores of 1000 patients under placebo (blue)
and under active treatment (red) for SDte = 6.5 and ρ = - 0.4. Fig 11 shows the magnitude of
the individual treatment effect of 100 individuals of this simulation.
Note that patients that would remain unchanged under placebo (response close to 0) have a
larger benefit from active medication (higher density of blue slopes) than patients that would
have improved under placebo. For some patients to benefit substantially, however, other
patients have to be harmed by the medication (red slopes). Without such a correlation, a TEH
of this magnitude would yield a VR of around 1.3.
Table 1. Upper bound on treatment effect heterogeneity compatible with the results.
Any distribution Normal distribution Dichotomous response
ρ SDte (HAMD17) % of patients with TE > 7 HAMD17 Responder TE (HAMD17) % Responders
-1.0 15.5 37.3 9.7 20.5
-0.8 12.4 34.4 8.2 24.3
-0.6 9.4 29.8 6.7 29.8
-0.4 6.5 22.1 5.2 38.1
-0.2 3.7 8.9 3.9 51.9
0.0 1.5 0.1 2.8 72.2
0.2 0.6 0.0 2.3 86.2
0.4 0.4 0.0 2.2 91.6
0.6 0.3 0.0 2.1 94.1
0.8 0.2 0.0 2.1 95.5
1.0 0.2 0.0 2.1 96.3
Assuming a VR of 1.02, a SDp of 7.66 points (based on Cipriani [10]) and different correlation coefficients ρ between the response under placebo and the treatment
effect. Left column (“any distribution”): Upper bounds for the standard deviation of the treatment effect. Mid column: Percentage of patients with TE greater than 7
HAMD17 points, when assuming a normal distribution of the TE with mean 2.0. Right column (“dichotomous response”): Patients are either “non-responders” with a
treatment effect of 0, or "responders” with the responder treatment effect. For a given correlation coefficient ρ, there is one possible solution for the treatment effect
(TE).
https://doi.org/10.1371/journal.pone.0241497.t001
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Fig 10. Change score of 1000 simulated patients. Boxplot (a) of change score under placebo (blue) and under active treatment (red) for ρ = - 0.4, SDte = 6.35
HAMD-17 points and VR = 1.02. (b) depicts pre-post change for each individual patient, gauged to 0. Note, that in this particular simulation, the SDte is not
exactly equal to 6.5, as all simulations contain random processes.
https://doi.org/10.1371/journal.pone.0241497.g010
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For the VR to be credibly lower than 1.02 and the response under placebo and the individ-
ual treatment effect to be uncorrelated (ρ = 0), TEH has to be low. S3 and S4 Figs depict the
results of a simulated experiment with SDte = 1.5 points on the HAMD-17 scale (derived from
Table 1). A VR closer to 1 would yield an even smaller treatment effect heterogeneity.
Discussion
Antidepressants are a first-line treatment for patients with major depressive disorder and are
widely prescribed around the world. Despite their widespread use, it remains unclear how
many and which patients benefit from this medication. In a recent re-analysis [6] of a highly
cited network meta-analysis [4], the average treatment effect of antidepressants was found to
be about 2 points on the HAMD-17 scale, which is almost undetectable by clinicians [7] and
lies below the assumed minimally clinically relevant effect [8, 9]. While this does not exclude
the possibility of subgroups of patients that have a meaningful benefit, substantial differences
in the individual treatment effect of antidepressants have not been shown to exist yet.
In search for evidence of benefiting subgroups, this work aimed to estimate the treatment
effect heterogeneity of antidepressants in the treatment of major depressive disorder using a
large dataset of a recent network meta-analysis [4]. To this end, we applied the effect size statis-
tics lnVR and lnCVR suggested by Nakagawa et al. [12], using a Bayesian random-effects
meta-analytical approach (REMA) and fitted a multi-level meta-regression (REMR) model to
estimate the treatment effect variability between antidepressants and placebo.
Both the lnVR REMR and the lnVR REMA, which were found to outperform the lnCVR
REMA, showed that the variability ratio was very close to 1 (REMR: 95% HDI [0.98, 1.02],
REMA: 95% HDI [1.00, 1.02]), compatible with a near-constant effect of antidepressants on
depression severity.
Subgroup and sensitivity analyses
We repeated the analyses for different antidepressant classes (SSRI, SSNRI, tricyclics and atypi-
cals) but did not detect clear evidence for treatment effect heterogeneity for any of the groups.
The estimates for SSRI, SSNRI and atypicals were relatively certain, while the VR for tricyclics
Fig 11. Potential outcomes and individual treatment effect of 100 simulated patients. Potential outcome under
placebo and under active treatment of 100 simulated patients, ρ = - 0.4, SDTE = 6.35 and VR = 1.2. Slopes represent
individual treatment effect, which varies substantially in this simulation. Blue lines indicated improvement under
active treatment, red lines deterioration.
https://doi.org/10.1371/journal.pone.0241497.g011
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yielded a wide credible interval with a mean estimate of 0.91 (95% HDI [0.60,1.28]), not clearly
suggestive of treatment effect heterogeneity.
Furthermore, we could not detect a relevant influence of baseline severity on outcome vari-
ability. Hence, even for severely depressed patients we found no evidence of subgroups that
have substantial benefit. This is in line with more recent analyses [26, 27] that could not con-
firm the previously assumed influence of baseline severity on antidepressant efficacy [28, 29].
In order to test the robustness of our finding, we repeated the main analysis using a more opti-
mistic prior, which did not alter the result.
Methodological aspects
Other research groups have addressed the same research question [14–16] using the same
dataset but have not considered important methodological aspects regarding the lnVR and
lnCVR effect sizes which demanded further inquiry.
When estimating the direct effect of antidepressants on outcome variability, the correlation
between the mean and standard deviation of the underlying measuring scale has to be taken
into account. In other words, how much of the difference in (logarithmic) variances is
explained by the difference in (logarithmic) means rather than directly by the treatment. The
lnVR and the lnCVR effect sizes naively assume a slope coefficient of 0 and 1 on this associa-
tion, respectively. Both may thus give biased results, if the true slope coefficient differs from
the one assumed.
By applying a varying intercept model taking into account the occurrence of different
depression scales we could show that the correlation between (logarithmic) mean and (loga-
rithmic) standard deviation is of a small magnitude (slope coefficient = 0.10), indicating that
the lnVR is a more appropriate measure as opposed to the lnCVR in this data set. The superi-
ority of the lnVR over the lnCVR was confirmed by the WAIC. Our work adds accuracy to the
existing literature, as we implemented a generalized meta-regression model (REMR) that
incorporates the slope coefficient for the correlation between lnMean and lnSD directly from
the data. This allowed us to disentangle the direct and indirect effect of antidepressants on out-
come variability.
Another important aspect that has not sufficiently been taken into account by previous
analyses is the occurrence of different depression scales. Naively regressing over all depression
scales may create a spurious correlation that is due to different means and SDs of these scales,
rather than a true lnMean ~ lnSD relationship. Indeed, a regression over all depression scales
yielded a slope coefficient of 0.25, which is 2.5 x as large as our estimate.
We addressed this issue by applying a contrast-based approach in the REMR. Here, each
antidepressant arm is compared to the respective placebo arm of the same study before data
pooling, thus resolving the issue of different depression scales across studies.
Upper bound for the treatment effect heterogeneity
Based on a recently derived inequation [25], we were able to established a direct relationship
between VR and treatment effect heterogeneity. We demonstrated that a VR of 1.02 (the upper
bound of the 95% HDI interval of the REMR) is theoretically compatible with a standard devi-
ation of the treatment effect between 0 and 15.5 HAMD-17 points. This translates into a maxi-
mum of 37% of patients with an individual treatment effect of more than 7 points when
assuming a normally distributed treatment effect. Such a large treatment effect heterogeneity
would require the treatment effect and the response under placebo of a patient to be strongly
and negatively correlated. In absence of such correlation, the treatment effect heterogeneity
would be negligibly small (SDte = 1.5 HAMD-17 points).
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How should these results be interpreted?
The VR is a measure that can potentially detect evidence for subgroups that benefit more than
average from an intervention. A VR that differs substantially from 1 is evidence of such sub-
groups, while a VR near 1 is compatible with both a small and a large treatment effect hetero-
geneity. So how should a VR of 1 (95% HDI [0.98,1.02]) be interpreted? For this, consider the
following illustration:
Hypothesis 1 (H1). The treatment effect heterogeneity is close to 0 (e.g. 99% of patients have
an individual treatment effect of 1 to 3 HAMD points).
Hypothesis 2 (H2). The treatment effect heterogeneity is greater than in H1.
There are now three possibilities:
1. H1 is true and VR� 1 (very close to 1, e.g. 0.98 to 1.02)
2. H2 is true and VR� 1
3. H2 is true and VR 6¼ 1 (not very close to 1)
Our results indicate that VR� 1. We can thus rule out the third possibility. From a Bayes-
ian perspective, the probability of H1 being true increases, while that of H2 being true
decreases.
In order for H2 to be true and the VR being close to 1, strong assumptions regarding the
correlation between the placebo response and the individual treatment effect of antidepres-
sants are necessary. Specifically, those patients whose depression severity would remain
unchanged under placebo would need to have the strongest antidepressant medication effect.
In the case of no such correlation, the treatment effect heterogeneity of antidepressants is likely
low. However, this correlation cannot be determined using summary statistics of randomized
controlled trial, as the inter-individual correlation of placebo-response and individual treat-
ment effect does not equal the correlation of sample mean response and average treatment
effect across studies. The direction of association may even be reversed, a phenomenon called
Simpson’s paradox.
Limitations
A limitation of this work is that we did not conduct an independent literature search and that
we did not use individual patient data which we did not have access to. All results are condi-
tional on the model assumptions. However, prior sensitivity analysis and subgroup analyses
did not alter the results. Other limitations were discussed by Munkholm et al. [15]. They
include the short duration of trials, as a varying treatment effect may only become apparent
after a longer period of time, and psychometrical limitations of the depression scales.
Conclusion
By applying a multiple level Bayesian regression model and simulations, this work could show
that the published data on antidepressants in the treatment of major depression is compatible
with a near-constant treatment effect, which is also the simplest explanation for the observed
data. Although is not possible to rule out a substantial treatment effect heterogeneity using
summary data from RCTs, we could show that a substantial treatment effect heterogeneity is
only compatible with the published data under strong assumptions that seem rather unlikely.
Until the existence of benefiting subgroups has been demonstrated prospectively, the average
treatment effect is the best estimator for the individual treatment effect. Since the average
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treatment effect of antidepressants probably falls short of clinical relevance, the current pre-
scribing practice in the treatment of major depression should be critically re-evaluated.
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